Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AMGN

AMGN - Amgen Inc Stock Price, Fair Value and News

$342.19-9.13 (-2.60%)
Market Closed

49/100

AMGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

49/100

AMGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$308.55

Target 3M

$335.44

Target 6M

$326.13

AMGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AMGN Price Action

Last 7 days

-0.4%

Last 30 days

3.8%

Last 90 days

17.2%

Trailing 12 Months

22.1%

AMGN RSI Chart

AMGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AMGN Valuation

Market Cap

184.3B

Price/Earnings (Trailing)

26.3

Price/Sales (Trailing)

5.12

EV/EBITDA

13.75

Price/Free Cashflow

15.97

AMGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$308.55

Target 3M

$335.44

Target 6M

$326.13

AMGN Fundamentals

AMGN Revenue

Revenue (TTM)

36.0B

Rev. Growth (Yr)

12.4%

Rev. Growth (Qtr)

4.12%

AMGN Earnings

Earnings (TTM)

7.0B

Earnings Growth (Yr)

13.64%

Earnings Growth (Qtr)

124.58%

AMGN Profitability

EBT Margin

22.92%

Return on Equity

72.82%

Return on Assets

7.77%

Free Cashflow Yield

6.26%

AMGN Investor Care

Dividend Yield

2.09%

Dividend/Share (TTM)

7.14

Shares Dilution (1Y)

0.18%

Diluted EPS (TTM)

12.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202534.1B34.9B36.0B0
202429.5B30.9B32.5B33.4B
202326.2B26.6B26.8B28.2B
202226.3B26.4B26.3B26.3B
202125.2B25.5B25.8B26.0B
202024.0B24.3B25.0B25.4B
201923.8B23.6B23.4B23.4B
201822.9B23.2B23.3B23.7B
201722.9B23.1B23.0B22.8B
201622.2B22.5B22.6B23.0B
201520.6B20.8B21.5B21.7B
201419.0B19.5B19.7B20.1B
201317.5B17.7B18.1B18.7B
201215.9B16.4B16.8B17.3B
201115.2B15.3B15.4B15.6B
201000015.1B
Get all data in R, Python etc through our Historical Stock Data APIs

About Amgen Inc

AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
 CEO
 WEBSITEamgen.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers General
 EMPLOYEES25200

Amgen Inc Frequently Asked Questions

AMGN is the stock ticker symbol of Amgen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Amgen Inc is 184.26 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AMGN's fair value in chart for subscribers.

The fair value guage provides a quick view whether AMGN is over valued or under valued. Whether Amgen Inc is cheap or expensive depends on the assumptions which impact Amgen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMGN.

As of Wed Jan 28 2026, AMGN's PE ratio (Price to Earnings) is 26.3 and Price to Sales (PS) ratio is 5.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMGN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Amgen Inc has provided 0.084 (multiply by 100 for percentage) rate of return.